OrbiMed entities tied to Peter Thompson exercise 210K CRVS shares (NASDAQ: CRVS)

Rhea-AI Filing Summary

Corvus Pharmaceuticals director and 10% owner Peter A. Thompson reported multiple option exercises linked to OrbiMed-affiliated entities. On 01/28/2026, stock options covering 210,000 shares of common stock were exercised at strike prices ranging from $0.965 to $15, resulting in 210,000 shares of common stock reported as directly owned.

An additional 8,609,091 shares of common stock are reported as indirectly owned through OrbiMed Private Investments V, LP and related OrbiMed entities. The filing states that Thompson, OrbiMed Advisors and OrbiMed Capital GP V LLC each disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Peter A.

(Last) (First) (Middle)

C/O CORVUS PHARMACEUTICALS, INC.

901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		M		30,000	A	$15	30,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$9.7	45,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$12.5	60,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$3.61	75,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$2	90,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$3.27	105,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$2.74	120,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$2.6	135,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$0.9899	150,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$0.965	165,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$2.49	180,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$1.64	195,000	D(1)
Common Stock	01/28/2026		M		15,000	A	$2.12	210,000	D(1)
Common Stock								8,609,091	I	See Footnotes(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15	01/28/2026		M			30,000	(4)	03/22/2026	Common Stock	30,000	$0	0	D(1)
Stock Option (Right to Buy)	$9.7	01/28/2026		M			15,000	(5)	06/08/2027	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$12.5	01/28/2026		M			15,000	(6)	06/21/2028	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$3.61	01/28/2026		M			15,000	(7)	06/20/2029	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$2	01/28/2026		M			15,000	(8)	03/19/2030	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$3.27	01/28/2026		M			15,000	(9)	06/09/2030	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$2.74	01/28/2026		M			15,000	(10)	06/15/2031	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$2.6	01/28/2026		M			15,000	(11)	09/09/2031	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$0.9899	01/28/2026		M			15,000	(12)	06/15/2032	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$0.965	01/28/2026		M			15,000	(13)	08/11/2032	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$2.49	01/28/2026		M			15,000	(14)	06/15/2033	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$1.64	01/28/2026		M			15,000	(15)	12/06/2033	Common Stock	15,000	$0	0	D(1)
Stock Option (Right to Buy)	$2.12	01/28/2026		M			15,000	(16)	06/13/2024	Common Stock	15,000	$0	0	D(1)

Explanation of Responses:

1. Pursuant to an agreement with OrbiMed Advisors LLC ("OrbiMed Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP ("OPI V"). As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.

2. These securities are held of record by OPI V. GP V is the general partner of OPI V, and OrbiMed Advisors, a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors.

3. Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

4. The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from March 22, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.

5. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

6. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

7. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

8. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.

9. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

10. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

11. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.

12. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

13. The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

14. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

15. The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

16. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

	/s/ Peter A. Thompson	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CRVS disclose for Peter A. Thompson?

Corvus Pharmaceuticals disclosed that stock options associated with director and 10% owner Peter A. Thompson were exercised for 210,000 shares of common stock on 01/28/2026. The resulting shares and related economic benefits are tied to OrbiMed-affiliated investment entities under pre-existing agreements.

How many Corvus Pharmaceuticals (CRVS) shares are indirectly held through OrbiMed entities?

The filing reports 8,609,091 shares of Corvus Pharmaceuticals common stock indirectly held by OrbiMed Private Investments V, LP. OrbiMed Capital GP V LLC and OrbiMed Advisors LLC may be deemed to share voting and investment power over these shares based on their roles with that investment vehicle.

What types of derivatives were exercised in this CRVS Form 4 filing?

The Form 4 shows exercises of multiple stock options (rights to buy common stock) on 01/28/2026. Each option series had its own exercise price and vesting schedule, with underlying shares converting into common stock as the options became exercisable under prior grant terms.

At what prices were Corvus Pharmaceuticals (CRVS) options exercised on 01/28/2026?

On 01/28/2026, stock options were exercised at a range of strike prices including $15, $9.7, $12.5, $3.61, $2, $3.27, $2.74, $2.6, $0.9899, $0.965, $2.49, $1.64, and $2.12, each converting into common shares.

Does Peter A. Thompson claim full beneficial ownership of the CRVS shares reported?

No. The filing states that Peter A. Thompson, OrbiMed Advisors and OrbiMed Capital GP V LLC each disclaim beneficial ownership of the reported securities, except to the extent of any pecuniary interest. The report specifies this should not be deemed an admission of beneficial ownership under Section 16.

Which entity officially holds the large indirect CRVS position in this Form 4?

The 8,609,091 indirectly owned shares of Corvus Pharmaceuticals common stock are held of record by OrbiMed Private Investments V, LP. OrbiMed Capital GP V LLC is its general partner, and OrbiMed Advisors LLC is the managing member that exercises investment and voting power through its management committee.